Investigation Report on China’s Doxorubicin Market 2021-2025 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 7, 2022--
The “Investigation Report on China’s Doxorubicin Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
According to the market research, the sales value of Doxorubicin in the Chinese market has increased year by year from 2016 to 2020. Especially, the sales of Doxorubicin in the Chinese market reached CNY 855 million in 2019, a year-on-year increase of 69.75%.
In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the growth rate of Doxorubicin’s sales value in the Chinese market has declined, but the sales still reached about CNY 1 billion in 2020. The CAGR of Doxorubicin’s sales value in the Chinese market is 38.60% in 2016 to 2020.
Doxorubicin belongs to the anthracycline class (Anthracycline) antibiotics, which can inhibit the synthesis of RNA and DNA. It has a strong inhibitory effect on RNA and has a broad anti-tumor spectrum. It has an effect on a variety of tumors. Doxorubicin was developed by Alza Corporation of the United States.
According to the market research, as of the end of 2020, the original Doxorubicin drug has not been listed in China, but many companies have obtained approval for the listing of generic drugs in China and have been included in the China National Medical Insurance Category A catalog. By 2020, there were 8 manufacturers in the Chinese Doxorubicin market, of which CSPC Ouyi Pharmaceutical Co., Ltd. was the main manufacturer.
The analyst expects that with the increase of cancer patients in 2021-2025, the sales volume of Doxorubicin in the Chinese market will increase steadily. Doxorubicin liposome injection has the advantages of targeting, sustained release, and reduced toxicity.
Based on these advantages, the sales volume and sales of Doxorubicin liposome injection will continue to increase. In addition, the alleviation of the COVID-19 epidemic will also cause the sales of Doxorubicin to show a recovery growth.
- The impact of COVID-19 on China’s Doxorubicin market
- Sales value of China’s Doxorubicin 2016-2020
- Competitive landscape of China’s Doxorubicin market
- Prices of Doxorubicin in China
- Prices of Doxorubicin in China by regions and manufacturers
- Analysis of factors affecting the development of China’s Doxorubicin market
- Prospect of China’s Doxorubicin market from 2021 to 2025
Key Topics Covered:
1 Relevant Concepts of Doxorubicin
1.1 Indications for Doxorubicin
1.2 Development of Doxorubicin in China
1.3 Governmental Approval of Doxorubicin in China
1.4 The Impact of COVID-19 on Doxorubicin sales in China
2 Sales of Doxorubicin in China, 2016-2020
2.1 Sales Value of Doxorubicin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Doxorubicin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Doxorubicin by Dosage Form in China, 2016-2020
2.3.2 Liposome Injection
3 Analysis of Major Doxorubicin Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Doxorubicin Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 CSPC Ouyi Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Duomeisu (CSPC Ouyi Pharmaceutical Co., Ltd.’s Doxorubicin) in China
3.3 Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Libaoduo (Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd.’s Doxorubicin) in China
3.4 Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Lixing (Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.’s Doxorubicin) in China
3.5 Shenzhen Main Luck Pharmaceuticals Inc.
3.5.1 Enterprise Profile
3.5.2 Sales of Shenzhen Main Luck Pharmaceuticals Inc.’s Doxorubicin in China
3.6 Shanxi Powerdone Pharmaceutics Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Shanxi Powerdone Pharmaceutics Co., Ltd.’s Doxorubicin in China
4 Prices of Doxorubicin for Different Manufacturers in China, 2020-2021
4.1 CSPC Ouyi Pharmaceutical Co., Ltd. (Duomeisu)
4.2 Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd. (Libaoduo)
4.3 Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. (Lixing)
4.4 Shenzhen Main Luck Pharmaceuticals Inc.
4.5 Shanxi Powerdone Pharmaceutics Co., Ltd.
5 Prospect of Chinese Doxorubicin Market, 2021-2025
5.1 Influential Factors of Chinese Doxorubicin Market Development
5.1.1 The Impact of COVID-19 on Chinese Doxorubicin Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/r/pv03mm
View source version on businesswire.com:https://www.businesswire.com/news/home/20220107005246/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: CHINA ASIA PACIFIC
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 01/07/2022 07:00 AM/DISC: 01/07/2022 07:02 AM